Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway

Cell Death and Disease

Volumn 9, Issue 1, 2018, Pages

  Wang, Meng He ^a,b   Sun, Rui ^a   Zhou, Xiao Min ^c   Zhang, Mei Yin ^a,b   Lu, Jia Bin ^a   Yang, Yang ^a,b   Zeng, Li Si ^d   Yang, Xian Zi ^d   Shi, Lu ^a,b   Xiao, Ruo Wen ^a,b   Wang, Hui Yun ^a,b   Mai, Shi Juan ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

^c Zhoukou Hospital of Traditional Chinese Medicine   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; EIF4EBP1 PROTEIN, HUMAN; EPITHELIAL CELL ADHESION MOLECULE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; RAPAMYCIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NASOPHARYNX CARCINOMA; NASOPHARYNX TUMOR; NUDE MOUSE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ANIMALS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, NUDE; MIDDLE AGED; NASOPHARYNGEAL CARCINOMA; NASOPHARYNGEAL NEOPLASMS; PHOSPHOPROTEINS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 85040367661     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-017-0013-8     Document Type: Article

References (44)

1. Cao, S. M., Simons, M. J. & Qian, C. N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin. J. Cancer 30, 114�119 (2011).
2. Zhang, L. F. et al. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis. Chin. J. Cancer 34, 350�357 (2015).
3. Sun, X. et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother. Oncol. 110, 398�403 (2014).
4. Jia, W. H. et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer 6, 178 (2006).
5. Colaco, R. J. et al. Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Clin. Oncol. 25, 171�177 (2013).
6. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495�497 (1975).
7. Herlyn, M., Steplewski, Z., Herlyn, D. & Koprowski, H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. Natl Acad. Sci. USA 76, 1438�1442 (1979).
8. Baeuerle, P. A. & Gires, O. EpCAM (CD326) finding its role in cancer. Br. J. Cancer 96, 417�423 (2007).
9. Trzpis, M., McLaughlin, P. M., de Leij, L. M. & Harmsen, M. C. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 171, 386�395 (2007).
10. Yanamoto, S. et al. Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol. 43, 869�877 (2007).
11. Ensinger, C., Kremser, R., Prommegger, R., Spizzo, G. & Schmid, K. W. EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. J. Immunother. 29, 569�573 (2006).
12. Benko, G., Spajic, B., Kruslin, B. & Tomas, D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol. Oncol. 31, 468�474 (2013).
13. Ni, J. et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int. J. Biochem. Cell Biol. 45, 2736�2748 (2013).
14. Massoner, P. et al. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205. Br. J. Cancer 111, 955�964 (2014).
15. Matsuda, T. et al. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma. Ann. Surg. Oncol. 21(Suppl 3), S356�S364 (2014).
16. Li, Y., Farmer, R. W., Yang, Y. & Martin, R. C. Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. BMC Cancer 16, 228 (2016).
17. Sun, Y. F. et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57, 1458�1468 (2013).
18. Went, P. et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br. J. Cancer 94, 128�135 (2006).
19. Hiraga, T., Ito, S. & Nakamura, H. EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation. Int. J. Cancer 138, 1698�1708 (2016).
20. Gao, J. et al. By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Oncotarget 6, 27187�27198 (2015).
21. Spizzo, G. et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol. Oncol. 103, 483�488 (2006).
22. Meng, Y. et al. Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection. Int. J. Clin. Exp. Med. 8, 22204�22216 (2015).
23. Varga, M. et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin. Cancer Res. 10, 3131�3136 (2004).
24. Zhou, N. et al. MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer. J. Exp. Clin. Cancer Res. 34, 157 (2015).
25. Warneke, V. S. et al. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. Br. J. Cancer 109, 2217�2227 (2013).
26. Eichelberg, C. et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int. J. Cancer 132, 2948�2955 (2013).
27. Patriarca, C., Macchi, R. M., Marschner, A. K. & Mellstedt, H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat. Rev. 38, 68�75 (2012).
28. Hwang, E. Y. et al. Decreased expression of Ep-CAM protein is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J. Oral Pathol. Med. 38, 87�93 (2009).
29. Kimura, H. et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int. J. Oncol. 30, 171�179 (2007).
30. Seligson, D. B. et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin. Cancer Res. 10, 2659�2669 (2004).
31. Songun, I. et al. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br. J. Cancer 92, 1767�1772 (2005).
32. Munz, M. et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23, 5748�5758 (2004).
33. Chaves-Perez, A. et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 32, 641�650 (2013).
34. Litvinov, S. V. et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J. Cell Biol. 139, 1337�1348 (1997).
35. Imrich, S., Hachmeister, M. & Gires, O. EpCAM and its potential role in tumor-initiating cells. Cell Adhesion Migr. 6, 30�38 (2012).
36. Liu, Y. et al. Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumour Biol. 33, 241�245 (2012).
37. Wang, W. et al. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma. PLoS ONE 9, e106098 (2014).
38. Song, L. B. et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119, 3626�3636 (2009).
39. Zhang, L. Y. et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 34, 454�463 (2013).
40. Zhou, X. M. et al. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget 7, 13634�13650 (2016).
41. Su, R. et al. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma. Hepatol. Res. 46, 1380�1391 (2016).
42. Fenouille, N. et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS ONE 7, e40378 (2012).
43. Maetzel, D. et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat. Cell Biol. 11, 162�171 (2009).
44. Yamashita, T., Budhu, A., Forgues, M. & Wang, X. W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 67, 10831�10839 (2007).